Perventricular device closure of congenital muscular ventricular septal defects

Carlos A.C. Pedra, Simone R.F. Pedra, Paulo Chaccur, Marcelo Jatene, Rodrigo N. Costa, Ziyad M. Hijazi, Zahid Amin

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Muscular ventricular septal defects (MVSDs) account for approximately 20% of all congenital ventricular septal defects. Large defects in infants result in early heart failure, failure to thrive and pulmonary hypertension. Although percutaneous closure of MVSDs has been employed safely and effectively in children, adolescents and adults, its application in the small infant (weight <6 kg) carries a higher risk for complications including arrhythmias, hemodynamic compromise, cardiac perforation, tamponade and death. Perventricular closure of such defects, introduced by Amin and coworkers in the late 1990s, has become an attractive treatment modality for these small and high-risk patients. Experience worldwide has shown that the procedure is feasible, reproducible, safe and effective. In this article, the authors review the indications, the step-by-step technique and the results of perventricular closure of MVSDs using the AMPLATZER® mVSD device (AGA Medical, MN, USA).

Original languageEnglish (US)
Pages (from-to)663-674
Number of pages12
JournalExpert Review of Cardiovascular Therapy
Issue number5
StatePublished - May 1 2010


  • Hybrid
  • Interventional catheterization
  • Muscular ventricular septal defects
  • Perventricular

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Perventricular device closure of congenital muscular ventricular septal defects'. Together they form a unique fingerprint.

Cite this